SPC249
Caplacizumab
Status:
VeittApplication date:
7.2.2019Application published:
15.2.2019Grant published:
15.11.2020
Max expiry date:
18.5.2031Next due date:
31.5.2027Medicine name:
CabliviMedicine for children:
No
Timeline
Today
7.2.2019Application
15.2.2019Publication
15.11.2020Registration
31.5.2027Expires
Marketing license
IS authorization number:
EU/1/18/1305Date:
26.9.2018
Foreign authorization number:
EU/1/18/1305Date:
31.8.2018
Owner
Name:
Ablynx N.V.Address:
Technologiepark 21, Ghent-Zwijnaarde BE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2444424
Annual fees
Number
Paid
Expires
Payer
Number: 1
Paid: 13.5.2026
Expires: 31.5.2027
Payer: Árnason Faktor ehf.